Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
Cytomegalovirus (CMV) infections in liver transplant recipients are common and result in significant morbidity and mortality. Intravenous ganciclovir or oral valganciclovir are the standard treatment for CMV infection. The present study investigates the efficacy of oral valganciclovir in CMV infecti...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4420490?pdf=render |
| _version_ | 1819100069689819136 |
|---|---|
| author | Jong Man Kim Choon Hyuck David Kwon Jae-Won Joh Young Eun Ha Dong Hyun Sinn Gyu-Seong Choi Kyong Ran Peck Suk-Koo Lee |
| author_facet | Jong Man Kim Choon Hyuck David Kwon Jae-Won Joh Young Eun Ha Dong Hyun Sinn Gyu-Seong Choi Kyong Ran Peck Suk-Koo Lee |
| author_sort | Jong Man Kim |
| collection | DOAJ |
| description | Cytomegalovirus (CMV) infections in liver transplant recipients are common and result in significant morbidity and mortality. Intravenous ganciclovir or oral valganciclovir are the standard treatment for CMV infection. The present study investigates the efficacy of oral valganciclovir in CMV infection as a preemptive treatment after liver transplantation.Between 2012 and 2013, 161 patients underwent liver transplantation at Samsung Medical Center. All patients received tacrolimus, steroids, and mycophenolate mofetil. Patients with CMV infection were administered oral valganciclovir (VGCV) 900mg/day daily or intravenous ganciclovir (GCV) 5mg/kg twice daily as preemptive treatment. Stable liver transplant recipients received VGCV.Eighty-three patients (51.6%) received antiviral therapy as a preemptive treatment because of CMV infection. The model for end-stage liver disease (MELD) score and the proportions of Child-Pugh class C, hepatorenal syndrome, and deceased donor liver transplantation in the CMV infection group were higher than in the no CMV infection group. Sixty-one patients received GCV and 22 patients received VGCV. The MELD scores in the GCV group were higher than in the VGCV group, but there were no statistical differences in the pretransplant variables between the two groups. AST, ALT, and total bilirubin levels in the GCV group were higher than in the VGCV group when CMV infection occurred. The incidences of recurrent CMV infection in the GCV and VGCV groups were 14.8% and 4.5%, respectively (P=0.277).Oral valganciclovir is feasible as a preemptive treatment for CMV infection in liver transplant recipients with stable graft function. |
| first_indexed | 2024-12-22T00:56:55Z |
| format | Article |
| id | doaj.art-6cc85175ef154fcfbbfd80353df1eada |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-22T00:56:55Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-6cc85175ef154fcfbbfd80353df1eada2022-12-21T18:44:18ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01105e012355410.1371/journal.pone.0123554Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.Jong Man KimChoon Hyuck David KwonJae-Won JohYoung Eun HaDong Hyun SinnGyu-Seong ChoiKyong Ran PeckSuk-Koo LeeCytomegalovirus (CMV) infections in liver transplant recipients are common and result in significant morbidity and mortality. Intravenous ganciclovir or oral valganciclovir are the standard treatment for CMV infection. The present study investigates the efficacy of oral valganciclovir in CMV infection as a preemptive treatment after liver transplantation.Between 2012 and 2013, 161 patients underwent liver transplantation at Samsung Medical Center. All patients received tacrolimus, steroids, and mycophenolate mofetil. Patients with CMV infection were administered oral valganciclovir (VGCV) 900mg/day daily or intravenous ganciclovir (GCV) 5mg/kg twice daily as preemptive treatment. Stable liver transplant recipients received VGCV.Eighty-three patients (51.6%) received antiviral therapy as a preemptive treatment because of CMV infection. The model for end-stage liver disease (MELD) score and the proportions of Child-Pugh class C, hepatorenal syndrome, and deceased donor liver transplantation in the CMV infection group were higher than in the no CMV infection group. Sixty-one patients received GCV and 22 patients received VGCV. The MELD scores in the GCV group were higher than in the VGCV group, but there were no statistical differences in the pretransplant variables between the two groups. AST, ALT, and total bilirubin levels in the GCV group were higher than in the VGCV group when CMV infection occurred. The incidences of recurrent CMV infection in the GCV and VGCV groups were 14.8% and 4.5%, respectively (P=0.277).Oral valganciclovir is feasible as a preemptive treatment for CMV infection in liver transplant recipients with stable graft function.http://europepmc.org/articles/PMC4420490?pdf=render |
| spellingShingle | Jong Man Kim Choon Hyuck David Kwon Jae-Won Joh Young Eun Ha Dong Hyun Sinn Gyu-Seong Choi Kyong Ran Peck Suk-Koo Lee Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients. PLoS ONE |
| title | Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients. |
| title_full | Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients. |
| title_fullStr | Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients. |
| title_full_unstemmed | Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients. |
| title_short | Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients. |
| title_sort | oral valganciclovir as a preemptive treatment for cytomegalovirus cmv infection in cmv seropositive liver transplant recipients |
| url | http://europepmc.org/articles/PMC4420490?pdf=render |
| work_keys_str_mv | AT jongmankim oralvalganciclovirasapreemptivetreatmentforcytomegaloviruscmvinfectionincmvseropositivelivertransplantrecipients AT choonhyuckdavidkwon oralvalganciclovirasapreemptivetreatmentforcytomegaloviruscmvinfectionincmvseropositivelivertransplantrecipients AT jaewonjoh oralvalganciclovirasapreemptivetreatmentforcytomegaloviruscmvinfectionincmvseropositivelivertransplantrecipients AT youngeunha oralvalganciclovirasapreemptivetreatmentforcytomegaloviruscmvinfectionincmvseropositivelivertransplantrecipients AT donghyunsinn oralvalganciclovirasapreemptivetreatmentforcytomegaloviruscmvinfectionincmvseropositivelivertransplantrecipients AT gyuseongchoi oralvalganciclovirasapreemptivetreatmentforcytomegaloviruscmvinfectionincmvseropositivelivertransplantrecipients AT kyongranpeck oralvalganciclovirasapreemptivetreatmentforcytomegaloviruscmvinfectionincmvseropositivelivertransplantrecipients AT sukkoolee oralvalganciclovirasapreemptivetreatmentforcytomegaloviruscmvinfectionincmvseropositivelivertransplantrecipients |